Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin

Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin (the BONANZA Study)

The goal of this retrospective study is to compare the effectiveness and cost-effectiveness of two mixed ovarian stimulation protocols in women undergoing in vitro fertilization (IVF).

The main questions it aims to answer are:

• Does the combination of follitropin delta + HP-hMG result in a higher number of utilizable blastocysts per treatment cycle compared to follitropin alfa + HP-hMG?
• Does the follitropin delta based mixed protocol reduce total gonadotropin dose and cost per usable blastocyst while maintaining or improving pregnancy outcomes?

Researchers will compare follitropin alfa (Gonal-F®) + HP-hMG (Menopur®) with follitropin delta (Rekovelle®) + HP-hMG (Menopur®) to determine which protocol improves ovarian response, embryology outcomes, pregnancy rates, and overall treatment cost-efficiency.

Inclusion Criteria:

• Women between 18-45 years included
• First ovarian stimulation cycle only
• Patients who used mixed protocols combining menotropin and follitropin alfa or delta
• Patients whose Rekovelle doses were prescribed using the algorithm based on AMH and weight.

Exclusion Criteria:

• Patients who did not follow the algorithm to determine follitropin delta dosing and who required dose adjustments during the stimulation
• Patients who took concomitant treatment, such as corticosteroids, low molecular weight heparin, nonsteroidal anti-inflammatory drugs, recombinant LH or intra-vaginal vasodilators
• Oocytes donation or fertility preservation cycles